Literature DB >> 11827637

Innovative strategies in the management of acute stroke.

Lawrence R Wechsler1.   

Abstract

Advances in acute stroke therapy are rapidly changing our approach to management of patients with ischemic stroke. Intravenous tissue-plasminogen activator (tPA) was the first treatment demonstrated in a randomized controlled trial to improve outcome if given within the first 3 hours of stroke onset. Subsequent trials failed to extend the time window for intravenous therapy beyond 3 hours. Intra-arterial thrombolysis provides an alternative approach, with several advantages over intravenous therapy. The major drawback is the additional time needed for the interventional procedure, and the equipment and personnel requirements. New strategies aimed at reducing the total time from stroke onset to recanalization of occluded arteries include a combined intravenous/ intra-arterial delivery of thrombolysis and mechanical devices. For the millions of stroke survivors, investigations are now underway into the possibility of improvement of function through neuronal transplantation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11827637     DOI: 10.1007/s11886-002-0026-4

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  41 in total

1.  Recovery of spatial learning by grafts of a conditionally immortalized hippocampal neuroepithelial cell line into the ischaemia-lesioned hippocampus.

Authors:  J D Sinden; F Rashid-Doubell; T R Kershaw; A Nelson; A Chadwick; P S Jat; M D Noble; H Hodges; J A Gray
Journal:  Neuroscience       Date:  1997-12       Impact factor: 3.590

2.  PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.

Authors:  G J del Zoppo; R T Higashida; A J Furlan; M S Pessin; H A Rowley; M Gent
Journal:  Stroke       Date:  1998-01       Impact factor: 7.914

3.  A pilot study of urokinase therapy in cerebral infarction.

Authors:  A P Fletcher; N Alkjaersig; M Lewis; V Tulevski; A Davies; J E Brooks; W B Hardin; W M Landau; M E Raichle
Journal:  Stroke       Date:  1976 Mar-Apr       Impact factor: 7.914

4.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

5.  Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro.

Authors:  P W Andrews
Journal:  Dev Biol       Date:  1984-06       Impact factor: 3.582

6.  Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial.

Authors: 
Journal:  Stroke       Date:  1997-11       Impact factor: 7.914

7.  Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro.

Authors:  P W Andrews; I Damjanov; D Simon; G S Banting; C Carlin; N C Dracopoli; J Føgh
Journal:  Lab Invest       Date:  1984-02       Impact factor: 5.662

8.  Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain.

Authors:  R P Simon; J H Swan; T Griffiths; B S Meldrum
Journal:  Science       Date:  1984-11-16       Impact factor: 47.728

9.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

10.  Transplanted human neurons derived from a teratocarcinoma cell line (NTera-2) mature, integrate, and survive for over 1 year in the nude mouse brain.

Authors:  S R Kleppner; K A Robinson; J Q Trojanowski; V M Lee
Journal:  J Comp Neurol       Date:  1995-07-10       Impact factor: 3.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.